March 2019

Unique Immunotherapy Combinations Provide an Optimistic Outlook in Early Urothelial Carcinoma Trials

March 11, 2019

Clinical Articles

Ongoing research seeks to boost objective response rates in urothelial cancer by developing biomarkers to predict which immune checkpoint inhibitors a patient is most likely to respond to and by testing these in combination with each other and other treatment types to increase both the number and duration of responses.

Maintenance Ixazomib Slows Progression in Myeloma

March 12, 2019

Clinical Articles

Gareth Morgan, MD, PhD, presented the findings for the final analysis from the phase III TOURMALINE-MM3 trial at the 2019 Transplantation and Cellular Therapy Meetings, where there was a 28% reduction in the risk of progression and death in patients with newly diagnosed multiple myeloma.

Significant Increases in Mortality Are Observed With Thrombotic Microangiopathy

March 15, 2019

Clinical Articles

In a review of over 300 hematopoietic cell transplantation cases, thrombotic microangiopathy occurred in as many as 36% of patients and significantly raised the risk of related death, according to findings reported at the 2019 Transplantation and Cellular Therapy Meetings.

Recognizing Endometrial Tumor Immune Features Is Key to Treatment Success

March 09, 2019

Clinical Articles

Identifying the inflamed tumors that are most likely to respond favorably to immunotherapeutics and, conversely, finding ways to treat noninflamed tumors are essential for successful application of immunotherapy in endometrial cancer, according to a presentation at the 2019 Society of Gynecologic Oncology Annual Winter Meeting.

Optimizing Adjuvant Strategies Extends RFS in High-Risk Melanoma

March 11, 2019

Clinical Articles

In his presentation at the 2019 Annual Practical Recommendations in Immuno and Molecular Oncology Meetingi, Sanjiv S. Agarwala, MD, reviewed survival statistics of patients with melanoma being treated at different stages of their disease.

Avoiding Overtreatment Saves Medicare $320M Over 3-Year Period in Older Men With Prostate Cancer

March 13, 2019

Clinical Articles

Overtreating men 70 years or older with prostate cancer cost Medicare more than $1.2 billion from 2004 to 2007, according to the results of a retrospective study using the Surveillance, Epidemiology, and End Results–Medicare linked database.

Focusing On Optimal Settings for Selective Internal Radiation Therapy in CRC With Liver Mets

March 12, 2019

Clinical Articles

In an interview with Targeted Therapies in Oncology, Michael Cusnir, MD, explained that Y-90 is a type of beta emitter that is extremely focused, which allows for the treatment to be localized without affecting healthy portions of the liver or other structures surrounding the liver; it is delivered to selectively embolize the liver.

Treatment Advancements in NSCLC Change Therapy Recommendations in 2019 NCCN Guidelines

March 12, 2019

Clinical Articles

Due to an active research landscape, the National Comprehensive Cancer Network Guidelines for non–small cell lung cancer have had 3 recent updates that include numerous clinically relevant recommendations.

Are Comorbid Conditions Excluding Otherwise Eligible Patients From Clinical Trial Enrollment?

March 13, 2019

Clinical Articles

The presence of comorbid conditions was associated with lower rates of clinical trial discussions between patients and their physicians, subsequently leading to decreased trial participation, according to an analysis performed by Southwest Oncology Group.

Greater Communication and Care Coordination Needed to Stimulate Growth of Immunotherapy, Says ACCC

March 14, 2019

Clinical Articles

Less than 20% of healthcare providers feel very comfortable administering and prescribing appropriate and timely treatment to manage adverse events associated with immuno-oncology therapy, according to an independent needs assessment conducted by the ACCC IO Institute.

CMS Mulls Opposition to Downsizing Part D Protected Drug Classes

March 15, 2019

Clinical Articles

The healthcare community is still awaiting a response from the Centers for Medicare & Medicaid Services to the opposition of the agency’s proposal to substantially revise the Medicare Part D protected drug classes.